Biopharma's Default Position: Drug Stocks Hold Up Against US Downgrade
This article was originally published in RPM Report
Economists are fretting that the US may be heading into a “lost decade” of stagnation. Will those fears help Big Pharma investors finally end a lost decade of their own?
You may also be interested in...
When it comes to health care reform, Democrats and Republicans don’t appear to agree on very much. But during a BIO annual meeting session, three key policymakers representing both sides of the aisle in the Senate and the Obama Administration did agree on one thing: it is time for industry to stop asking to be “carved out” of new payment systems, and to start proving the value of its products.
On July 21, Roche reported strong first half sales of Lucentis. It was all downhill from there.
It appeared as though the controversy over the level of efficacy and benefit from the prostate cancer immunotherapy Provenge ended when the drug was approved by FDA at the end of April. The FDA approval may have just been the halfway point in the product's route through government agencies to the commercial market. Now Medicare is questioning whether the government should pay for the new therapy. The CMS decision is just as important to the biopharmaceutical industry as it is to Dendreon.